Second quarter sales grew 4.8% with adjusted EPS of $1.31, exceeding expectations. Full-year sales growth guidance was reaffirmed and EPS guidance raised, with strong momentum in nutrition, diagnostics, and medical devices. Key product launches and pipeline investments support future growth.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.